George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
And not a word or peep out of Nobinpis.
Just hold, we can and will push this over the finish line.
Frits
Mrbrain
I suspect the NOMAD required this point about "no guarantee"
"Whilst there can be no guarantee of completing commercial deals, there are a broad range of discussions currently taking place and the objective is to complete deal(s) across the portfolio in 2024.
All very true though worth adding that the NOMAD would have had to have seen something to justify the expectations being put in an RNS, e.g. the nature and current state of partnership discussions.
Unless there is absolute 100% certainty, the choice of words is appropriate.
I am encouraged and have acquired more this morning.
Be careful with the wording of the RNS
All Tim has said is that "immediate" requirements are covered ...and that there are no " current" plans for equity raise
so be careful with the carefully chosen words , that allows for a change of circumstances beyond "current"
.. although it does support the notion that the Results would go through the auditor " as a going concern"
" Future cash requirements are fully expected to be met through non-dilutive income "...
"expected"... again carefully chosen so as not to commit to anything as it is all dependent on success of the "active discussions"
so.... Tim has carefully given himself an open door still to equity ...if... the developments don't in fact work out
..although the use of the word "expected" is positive
Way
Hard to find profit when already 90%down. This has a long watt to run now. GLA
Buying back in heavily today, I got it wrong, partner deals clearly very close or they would not have put out a statement saying no more dilution expected, they cannot legally do that unless partner deals are very well advanced or it would not have got approved by nomad
1.4
UP 50%
Mr Brain
Good summary. I couldn't put in better myself.
I am buying again today and order in
Atb
Always., always take your profit on these rises .
Up 40%
Outstanding RNS. Remember IMM is currently priced to go bust, despite holding significant assets and today it being confirmed that there are no current plans to raise equity and that future cash requirements are expected to be non dilutive from up front payments in new commercial deals with unpartnered assets. Active discussions / a bread range of discussions confirmed.
Among the assets are:
1. Fully funded P3 trial for Lupuzor, which IMM has double digit tiered royalties on up to 17% and milestone payments, whilst retaining all non-US rights that they hope to partner on this year. The US only deal itself is worth more than the current market cap, let alone the ROW rights that they can sell.
2. They have the worldwide rights for Lupuzor in CIPD that can go straight into a P2/3 and which they hope to partner on. Again, any deal would dwarf the current market cap. Orphan drug status being submitted which again would provide a large boost to the SP even before a deal.
3. The worldwide rights for BioAMB, an anti-infective program that they also hope to partner on. Part 1 of new dose ranging study in animal model complete and no toxisity. Moving to Part 2. Intial partnering discussions have commenced.
4. IMM owns 10.8% (as well as 7.3m warrants) in Incanthera, which concluded a significant commercial skincare deal with part of the AS Watson Group. This is the world's largest international health and beauty retailer owning brands like Superdrug, The Perfume Shop and many others. Significant revenues and profitability are expected to commence for Incanthera in 2024.
5. Overheads reduced by more than 75% since the new business plan came in.
All for a market cap of £4.7m. Yes, sub £5m market cap, with no funding needs, for double digit royalties in a fully funded P3 trial, 100% of ROW rights to sell for that trial, 100% of CIDP worldwide rights to sell for the same drug to go into P2/3 trial, 10.8% share of a company expected to generate revenues and profitability this year with a partnership with the world's largest international health and beauty retailer, anti-infective progress and partnership discussions having commenced, and overheads reduced by 75%.
It is in my view one of the most undervalued companies on AIM. It should easily have a market cap of £20m in its current position, or around 5p. And that is before any deals are done.
Ooops - That's what I should have said
Well a price back up to the recent placing looks on the cards. I have just added again
Not for long though on the basis of the RNS - also continually going into auction this morning , should be the top of the risers list for the rest of the day and week.
GLA SR
I told that idiot the other day who kept talking of administration the company would NOT do a fundraise and they had options to sell licence and or sell an asset. Seem to be just that. Now where is that guy gone? Has he disappeared?
Can never be right and was a bit of a gamble tbh, but it will pay off here - top riser and money inbound
.this delay was deliberately done...in my opinion
This Update should have been a 2023 Year End Update ...long before now..given nothing was released since Interims regarding the whole company
I blame Tim..not acceptable ..this delay was deliberately done
WELL DONE MAVERICKD
One of the few who called it correct and bought the dip.
Progress is being made and money will be coming in
On the way……alll the mis-information last few weeks
UP 38%
FLYING NOW